Core Viewpoint - Weigao Blood Purification announced plans to acquire 100% equity of Weigao Purui Pharmaceutical Packaging for approximately 8.511 billion yuan through a share issuance, with a share price of 31.29 yuan, reflecting a 25% discount from the closing price on January 5 [1] Group 1: Transaction Details - The acquisition price of Weigao Purui is based on a valuation using the income approach, with a premium rate of 192.90% as of the assessment date of September 30, 2025 [1] - The share issuance price is set at 31.29 yuan per share, which is 80% of the average trading price over the previous 20 trading days [1] - Post-transaction, the controlling shareholder will change from Weigao Group to Weigao Co., while the actual controller remains Chen Xueli [1] Group 2: Financial Impact - Following the acquisition, the listed company's revenue is projected to increase by 51.56% and net profit attributable to shareholders by 142.57% for the first three quarters of 2025 [2] - Total assets of the listed company are expected to rise by 42.23% by the end of the period [2] - For 2024, revenue and net profit are anticipated to grow by 46.39% and 129.22%, respectively [2] Group 3: Market Position and Growth Potential - Weigao Purui holds the largest market share in pre-filled drug delivery systems in China, exceeding 50% from 2022 to 2024 [2] - The demand for pre-filled drug delivery systems and automatic safety drug delivery systems is rapidly increasing due to the growth of the biopharmaceutical and vaccine industries [3] - The transaction is expected to enhance the listed company's profitability and investment value by integrating Weigao Purui's strong asset base and technology with the company's existing capabilities [3]
威高血净拟85亿元收购威高普瑞